Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting

MALVERN, Pa., April 24, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it will sponsor a symposium on Janus Kinase (JAK) inhibitors at the 76^th Annual Society for Investigative Dermatology Meeting in Portland, Oregon. The symposium, titled “You Don’t Know JAK,” will be held on Thursday, April 27, 2017, from 12:00-1:45 PM PST. Poster presentations include:

• Clinical investigation of JAK inhibitor tofacitinib in scarring alopecias: Lindsey Bordone, MD, Columbia University, New York, NY, Abstract #075
   
• Treatment of vitiligo with topical Janus Kinase inhibitor ruxolitinib: Brooke Rothstein, Tufts Medical Center, Boston, MA, Abstract #770
   
• Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials: James Chen, PhD, Columbia University, New York, NY, Abstract #397

Dr. Neal Walker, President and Chief Executive Officer, and Dr. Stuart Shanler, Chief Scientific Officer, will be in attendance. Following the poster presentations, there will be a panel discussion and question and answer session with presenters. 

Additional information on the 76^th Annual Society of Investigative Dermatology Meeting can be found at: http://www.sidnet.org/news/339026/View-the-2017-Annual-Meeting-Program.htm

About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania.

Contact:
Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
[email protected]

Media Contact
Mariann Caprino
TogoRun
917-242-1087
[email protected]